Editas Medicine, Inc. 8-K

What Happened

• On May 26, 2026 Editas Medicine, Inc. announced it notified TD Securities (USA) LLC (TD Cowen) that it was suspending and terminating the prospectus supplement dated March 21, 2025 related to its sales agreement (the “Sales Agreement”) for an at-the-market (ATM) offering of common stock.
• The company said it will not make any sales of its common stock under the Sales Agreement unless and until a new prospectus or prospectus supplement is filed and, if applicable, a new registration statement covering such shares is declared effective by the SEC. The Sales Agreement itself remains in full force and effect.

Key Details

• Date of notice: May 26, 2026.
• Original Sales Agreement entered May 14, 2021; amended Feb 28, 2024 and Mar 5, 2025. Prospectus supplement suspended: March 21, 2025 supplement.
• Shares sold under the ATM program to date: 14,327,365 shares.
• Aggregate gross proceeds from those sales: $43.9 million (before sales commissions and offering expenses).

Why It Matters

• For investors, the immediate effect is that Editas has paused its ability to sell additional shares through the TD Cowen ATM program until a new prospectus/registration is effective, which limits that particular near-term source of equity financing.
• The company has previously used the ATM to raise capital ($43.9M gross to date), but the filing indicates any future use requires renewed SEC effectiveness — the Sales Agreement remains active, so the program could resume once the company files and obtains effectiveness for a new prospectus or supplement.